Anti-human interleukin-17A monoclonal antibody
An anti-human IL-17A monoclonal antibody, the preparation method, and the use thereof are provided. The anti-human IL-17A monoclonal antibody can specifically bind to human IL-17A and has a good effect for inhibiting the secretion of inflammatory cytokines, such as IL-6 and the like by means of various cell lines induced by IL-17A, and can be used for preparing drugs for treating diseases involving immune-medicated inflammatory responses.
1. An isolated anti-human IL-17A monoclonal antibody comprising:
(1) a heavy chain variable region comprising CDR1, CDR2 and CDR3, wherein the CDR1 has the amino acid sequence of SEQ ID NO: 5, the CDR2 has the amino acid sequence of SEQ ID NO: 6, and the CDR3 has the amino acid sequence of SEQ ID NO: 7; and
(2) a light chain variable region comprising CDR1′, CDR2′ and CDR3′, wherein the CDR1′ has the amino acid sequence of SEQ ID NO: 8, the CDR2′ has the amino acid sequence of SEQ ID NO: 9, and the CDR3′ has the amino acid sequence of SEQ ID NO: 10.
2. The anti-human IL-17A monoclonal antibody of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 2, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 4.
3. The anti-human IL-17A monoclonal antibody of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 12, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 14, and wherein the antibody is a humanized antibody.
4. The anti-human IL-17A monoclonal antibody of claim 3 , comprising a heavy chain having the amino acid sequence of SEQ ID NO: 15, and a light chain having the amino acid sequence of SEQ ID NO: 16.
5. A composition, comprising the anti-human IL-17A monoclonal antibody of claim 1 and a pharmaceutically acceptable carrier.
6. An isolated polynucleotide encoding the anti-human IL-17A monoclonal antibody of claim 1 .
7. The polynucleotide of claim 6 , wherein the nucleotide sequence encoding the heavy chain variable region of the antibody comprises SEQ ID NO:1, and the nucleotide sequence encoding the light chain variable region of the antibody comprises SEQ ID NO:3.
8. The polynucleotide of claim 6 , wherein the nucleotide sequence encoding the heavy chain variable region of the antibody comprises SEQ ID NO:17, and the nucleotide sequence encoding the light chain variable region of the antibody comprises SEQ ID NO:18.
9. The polynucleotide of claim 6 , wherein the nucleotide sequence encoding the heavy chain variable region of the antibody comprises SEQ ID NO:11, and the nucleotide sequence encoding the light chain variable region of the antibody comprises SEQ ID NO:13.
10. The polynucleotide of claim 6 , wherein the nucleotide sequence encoding the heavy chain variable region of the antibody comprises SEQ ID NO:19, and the nucleotide sequence encoding the light chain variable region of the antibody comprises SEQ ID NO:20.
11. An expression vector, comprising the polynucleotide of claim 6 .
12. An isolated host cell, comprising the expression vector of claim 11 .
13. A method of preparing an anti-human IL-17A monoclonal antibody encoded by the polynucleotide in the expression vector in the host cell of claim 12 , comprising the steps of: a) culturing the host cell under suitable conditions to express the antibody; and b) isolating and purifying the expressed antibody.